NCT07063173 Bioavailability of Ration Items Containing Tart Cherry Extract
| NCT ID | NCT07063173 |
| Status | Recruiting |
| Phase | — |
| Sponsor | United States Army Research Institute of Environmental Medicine |
| Condition | Bioavailability |
| Study Type | INTERVENTIONAL |
| Enrollment | 15 participants |
| Start Date | 2024-06-14 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 15 participants in total. It began in 2024-06-14 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To determine how consuming food items containing shelf-stored tart cherry impacts your body's ability to absorb and use the compounds within tart cherry.
Eligibility Criteria
Inclusion Criteria: * Active duty military personnel and civilians will be invited to participate in the study if they: * Are between the ages of 18 (or 17 for military personnel) and 39. * Are willing to participate in all study procedures and comply with all study instruction. * In good health as determined by OMSO (Office of Medical Support and Oversight). * Supervisor approval for federal civilian employees and non-HRV active-duty military personnel stationed at NSSC Exclusion Criteria: * • Unable to understand verbal or written instructions or testing materials in English. * Have a bleeding disorder (e.g., von Willebrand Disease, hemophilia) or are being treated with medication that will impair blood clotting (for example, coumadin) * Have a history of GI-related conditions that may impact macronutrient absorption (e.g., Crohn's disease, ulcerative colitis, Celiac's disease or gluten sensitivity, bariatric surgery or gastroparesis, short bowel, inflammatory bowel disease, etc…); * Any use of antibiotics or antifungal, except topical antibiotics/antifungals within 3 months of study participation. * Colonoscopy within 3 months of study participation. * Regular (i.e., weekly or more frequent) use of over-the-counter medications (including antacids, laxatives, stool softeners, and antidiarrheals) unless approved by OMSO and study PI. * Are habitually taking nonsteroidal anti-inflammatory drugs (e.g., Advil, aspirin), corticosteroids (e.g., prednisone) or immunosuppressants (e.g. Humira); * Have an allergy or aversion (extreme dislike) to any of the test foods(e.g., cherry flavored beverages or bar). Allergy symptoms may include anaphylaxis, hives or eczema, tingling/itching in the mouth, dizziness or fainting, diarrhea, nausea or vomiting, swelling of the lips, face, tongue and throat). * Have donated blood within the past 8 weeks of the first test session or plan to donate blood during the study. * Are not willing to abstain from tobacco products and vigorous exercise for at least 24 hours" before each trial and consume a low-polyphenol diet two days prior to each test session and on the day of the test session.
Contact & Investigator
Tracey Smith, PhD
PRINCIPAL INVESTIGATOR
United States Army Research Institute of Environmental Medicine
Frequently Asked Questions
Who can join the NCT07063173 clinical trial?
This trial is open to participants of all sexes, aged 17 Years or older, up to 39 Years, studying Bioavailability. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07063173 currently recruiting?
Yes, NCT07063173 is actively recruiting participants. Contact the research team at tracey.smith10.civ@health.mil for enrollment information.
Where is the NCT07063173 trial being conducted?
This trial is being conducted at Natick, United States.
Who is sponsoring the NCT07063173 clinical trial?
NCT07063173 is sponsored by United States Army Research Institute of Environmental Medicine. The principal investigator is Tracey Smith, PhD at United States Army Research Institute of Environmental Medicine. The trial plans to enroll 15 participants.